drugset / Trial / NCT02408042
Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To determine the recommended phase 2 dose of chemotherapy in combination with Pembrolizumab in subjects with advanced lymphoma and determine the complete response rate.
Timeline
- Start
- 2015-04
- Primary completion
- 2015-11
- Completion
- 2015-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Brentuximab Vedotin | Monoclonal antibody | — | — |
| Comparator | Carboplatin | Small molecule | — | — |
| Comparator | Etoposide | Small molecule | — | — |
| Comparator | Ifosfamide | Small molecule | — | — |
| Comparator | Rituximab | Monoclonal antibody | — | — |
| Comparator | 2-MERCAPTOETHANESULFONIC ACID | Small molecule | — | — |
| Comparator | Pembrolizumab | Monoclonal antibody | — | — |